A bruised Eli Lilly buys rights to Centrexion’s early-stage pain drug for $47.5M upfront

On Tuesday, the US drugmaker said it was acquiring the rights to an experimental early-stage non-opioid pain drug from Centrexion for $47.5 million upfront. The Boston-based company acquired the chronic pain drug CNTX-0290 — a small molecule somatostatin receptor type 4 (SSTR4) agonist — from Boehringer Ingelheim in 2016.